← Leaderboards
Samarendra Kumar Mohanty
University Of Texas Arlington
$10,109,628
Attributed
$12,775,737
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,775,737 · 7
By mechanism
R44$7,362,618 · 3
R01$3,665,360 · 2
U01$1,571,637 · 1
R21$176,122 · 1
Top collaborators
- Weldon Wright4 shared
- Adnan Ismail Dibas2 shared
- Qifa Zhou2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsRetinaSuccessMouse ModelBlindnessIn VivoBasePhotoreceptorsRetinal DegenerationLightOptogeneticsOpsinResolutionIntravitreal InjectionElectrophysiology (Science)Electric StimulationVisionResponseSignal TransductionImplantationRestorationSourceGenesPhotoreceptor Degeneration
Grant awards (26)
Sonogenetic Restoration of Vision for Retinitis Pigmentosa$786,257
U01 · FY2025 · EY · contact PI
Sonogenetic Restoration of Vision for Retinitis Pigmentosa$785,380
U01 · FY2024 · EY · contact PI
Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment$875,350
R44 · FY2023 · EY
Ambient light activatable opsin based therapy for age-related macular degeneration$737,805
R44 · FY2022 · EY · contact PI
Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment$716,879
R44 · FY2022 · EY
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy$656,220
R44 · FY2022 · EY · contact PI
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$375,875
R01 · FY2022 · EY · contact PI
Ambient light activatable opsin based therapy for age-related macular degeneration$749,517
R44 · FY2021 · EY · contact PI
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy$678,626
R44 · FY2021 · EY · contact PI
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$375,875
R01 · FY2021 · EY · contact PI
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy$779,869
R44 · FY2020 · EY · contact PI
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$387,500
R01 · FY2020 · EY · contact PI
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$384,200
R01 · FY2020 · EY · contact PI
AMBIENT LIGHT ACTIVATABLE OPSIN BASED THERAPY FOR AGE-RELATED MACULAR DEGENERATION$77,597
R44 · FY2020 · EY · contact PI
Ambient light activatable opsin based therapy for age-related macular degeneration$950,373
R44 · FY2019 · EY · contact PI
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$493,520
R01 · FY2019 · EY · contact PI
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$484,950
R01 · FY2019 · EY · contact PI
Ambient light activatable opsin based therapy for age-related macular degeneration$109,200
R44 · FY2019 · EY · contact PI
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$75,240
R01 · FY2019 · EY · contact PI
Ambient light activatable opsin based therapy for age-related macular degeneration$1,031,182
R44 · FY2018 · EY · contact PI
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$274,200
R01 · FY2018 · EY · contact PI
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$247,500
R01 · FY2018 · EY · contact PI
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$71,500
R01 · FY2018 · EY · contact PI
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$247,500
R01 · FY2017 · EY · contact PI
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$247,500
R01 · FY2016 · EY · contact PI
All optical control and monitoring of neural activity$176,122
R21 · FY2013 · NS · contact PI